Mainz Biomed's pancreatic cancer project receives public funding from ISB to enhance early detection diagnostics.
Quiver AI Summary
Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz. This funding will cover up to 50% of the project's costs as part of the ISB's Innovation and Technology Support Program, which highlights the importance of Mainz Biomed's non-invasive blood-based screening test aimed at early pancreatic cancer detection. The project is currently in the feasibility phase, employing a panel of mRNA biomarkers and a machine learning algorithm in collaboration with Crown Bioscience. This initiative is part of Mainz Biomed's broader strategy to expand accessible cancer diagnostics, with its flagship product being ColoAlert® for colorectal cancer.
Potential Positives
- Mainz Biomed's pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz, covering up to 50% of the project's total costs, providing significant financial support.
- The governmental funding is a strong endorsement of Mainz Biomed's non-invasive testing technology, highlighting its scientific and societal value in early cancer detection.
- The project aims to address a critical gap in cancer diagnostics by enabling earlier detection of pancreatic cancer, potentially improving patient outcomes.
- Mainz Biomed is collaborating with Crown Bioscience to evaluate advanced diagnostic methods, which could strengthen its position in the oncology market and expand its product portfolio.
Potential Negatives
- The project is currently in the feasibility phase, indicating it is still in early development and has not yet proven its effectiveness or market viability.
- There are inherent risks associated with the forward-looking statements, suggesting potential for significant variability in future outcomes and development timelines.
- The press release mentions the possibility of changes in applicable laws or regulations, which could impact the project's progress or funding negatively.
FAQ
What funding has Mainz Biomed received for its pancreatic cancer project?
Mainz Biomed's pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz, covering up to 50% of total costs.
What is the significance of the funding from ISB?
The funding is a strong endorsement of Mainz Biomed's non-invasive screening test for pancreatic cancer, enhancing its development potential.
What is the main objective of Mainz Biomed's pancreatic cancer project?
The project aims to detect pancreatic cancer at an earlier, more treatable stage, addressing a critical gap in cancer diagnostics.
What technologies are being evaluated in the project?
Mainz Biomed is assessing a panel of mRNA biomarkers and a machine learning-driven algorithm using real clinical blood samples.
What is the flagship product of Mainz Biomed?
Mainz Biomed's flagship product is ColoAlert®, an early-detection diagnostic test for colorectal cancer, marketed across Europe and the UAE.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYNZ Hedge Fund Activity
We have seen 0 institutional investors add shares of $MYNZ stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITIGROUP INC removed 17 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $73
- MORGAN STANLEY removed 5 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $21
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) , the development bank of the German federal state of Rheinland-Pfalz.
Under the ISB’s Innovation and Technology Support Program ( Innovations- und Technologieförderungsprogramm ), the state will fund up to 50% of the project’s total costs. This direct governmental support represents a strong endorsement of the scientific and societal value of Mainz Biomed’s non-invasive, blood-based screening test for the early detection of pancreatic cancer and will accelerate its development.
The award of the public grant underscores the medical and technological relevance of Mainz Biomed’s approach. The project aims to close a critical gap in cancer diagnostics by detecting pancreatic cancer at an earlier, more treatable stage.
“This support from the ISB is a strong vote of confidence in the potential of our technology and the importance of early detection in combating pancreatic cancer,” said Dr. Moritz Eidens, CSO of Mainz Biomed.
The project is currently in the feasibility phase. Together with Crown Bioscience, Mainz Biomed is evaluating the performance of a panel of mRNA biomarkers and a ML-driven algorithm, using real clinical blood samples. This work is part of the Company’s broader pipeline strategy to expand its portfolio of accessible, non-invasive diagnostics across multiple cancer indications.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert
®
, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert
®
is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit
mainzbiomed.com
or follow us on
LinkedIn
,
Twitter
and
Facebook
.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
[email protected]
For investor inquiries, please contact [email protected]
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
